Isa-VRd Standard of Care: Long-Term Benefit Data in Transplant-Ineligible NDMM

Isa-VRd Standard of Care: Long-Term Benefit Data in Transplant-Ineligible NDMM

December 7, 2025 Dr. Jennifer Chen Health

Here’s⁢ a breakdown of the provided references, formatted for clarity:

1. Conference Abstract:

* ‍ authors: A, ⁣Lambert J,‍ Corre J, ⁢et al.
* ⁢ ⁣⁢ title: Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated wiht isatuximab plus ‍lenalidomide adn dexamethasone with bortezomib (Isa-VRd) versus isa-rd:⁤ 12-24-month data from the phase ⁣3 benefit trial (IFM 2020-05).
* ‌ Meeting: 67th‌ American Society of Hematology (ASH) Annual Meeting ​and Exposition
* Date: December 6, 2025
* ⁤ Location: ‍Orlando, Florida
* Access Date: December 6,​ 2025
* Link: https://meetings-api.hematology.org/api/abstract/vmpreview/298506

2. Clinical Trial Registration:

* ⁢ Title: Multicenter open ⁢label phase 3 study of isatuximab plus lenalidomide⁣ and dexamethasone with/without bortezomib in the treatment of newly diagnosed non frail transplant ineligible‍ multiple myeloma‌ elderly patients.
* Identifier: NCT04751877
* Last Updated: September 7, 2022
* Access Date: December 6, 2025
* Link: https://clinicaltrials.gov/study/NCT04751877